

# Destiny Pharma looking to move on to phase III with XF-73 nasal gel



NEWS RELEASE BY DESTINY PHARMA PLC

London, UK | March 27, 2023 08:31 AM Eastern Daylight Time



Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief executive Neil Clark speaks to Thomas Warner from Proactive after publishing research about the company's new nasal gel, called XF-73, in the US journal 'Infection Control & Hospital Epidemiology'.

Clark explains more about the benefits of the gel and how it works, and confirms that the plan is to find a partner to help fund a phase III study.

## Contact Details

Proactive UK Ltd

+44 20 7989 0813

[uk@proactiveinvestors.com](mailto:uk@proactiveinvestors.com)

## Tags

HEALTH

PHARMA

EPIDEMIOLOGY